{"id":538,"date":"2022-04-21T18:15:06","date_gmt":"2022-04-21T23:15:06","guid":{"rendered":"https:\/\/nuvaira.com\/patient-selection\/"},"modified":"2022-07-27T11:47:59","modified_gmt":"2022-07-27T16:47:59","slug":"patient-selection","status":"publish","type":"page","link":"https:\/\/nuvaira.com\/fr\/patient-selection\/","title":{"rendered":"Crit\u00e8res d\u2019\u00e9ligibilit\u00e9 des patients"},"content":{"rendered":"
\n
\n
\n\n

Crit\u00e8res d\u2019\u00e9ligibilit\u00e9 des patients pour l\u2019essai AIRFLOW-3 <\/h1>\n
\n

AIRFLOW-3 est le premier essai interventionnel majeur visant \u00e0 r\u00e9duire les exacerbations chez les patients atteints de BPCO tr\u00e8s symptomatiques. <\/span><\/p>\n <\/div>\n \n \n

\n \n Contactez-nous pour en savoir plus sur le processus d\u2019orientation des patients <\/i>\n <\/a>\n \n Recherchez un centre d\u2019essai clinique <\/i>\n <\/a>\n <\/div>\n \n \n\n <\/div>\n <\/div>\n<\/div>\n\n\n
\n
\n
\n\n
\n\n

Jusqu\u2019\u00e0 400 patients <\/p>\n \n

Principaux crit\u00e8res de s\u00e9lection des patients<\/h2>\n \n \n <\/div>\n\n \n <\/div>\n <\/div>\n\n<\/div>\n\n\n\n\n
\n
\n\n
\n
\n <\/i>\n <\/div>\n \n

\n Diagnostic de BPCO VEMS 25-80 % post-bronchodilatateur<\/strong>\n <\/h3>\n
\n <\/div>\n <\/div>\n
\n
\n <\/i>\n <\/div>\n \n

\n \u00c2ge de 40 ans et plus IMC 18-35<\/strong>\n <\/h3>\n
\n <\/div>\n <\/div>\n
\n
\n <\/i>\n <\/div>\n \n

\n Tr\u00e8s symptomatique<\/strong>\n <\/h3>\n
\n <\/div>\n <\/div>\n
\n
\n <\/i>\n <\/div>\n \n

\n Exacerbations de la BPCO 2+ mod\u00e9r\u00e9es OU 1+ s\u00e9v\u00e8re(s) au cours des 12 derniers mois<\/strong>\n <\/h3>\n
\n <\/div>\n <\/div>\n
\n
\n <\/i>\n <\/div>\n \n

\n Arr\u00eat du tabac 2+ mois<\/strong>\n <\/h3>\n
\n <\/div>\n <\/div>\n
\n
\n <\/i>\n <\/div>\n \n

\n Bith\u00e9rapie ou trith\u00e9rapie<\/strong>\n <\/h3>\n
\n <\/div>\n <\/div>\n
\n
\n <\/i>\n <\/div>\n \n

\n Vaccination grippale \u00e0 jour<\/strong>\n <\/h3>\n
\n <\/div>\n <\/div>\n
\n
\n <\/i>\n <\/div>\n \n

\n Resting SpO2<\/sub> au repos \u2265 89 % en air ambiant<\/strong>\n <\/h3>\n
\n <\/div>\n <\/div>\n
\n
\n <\/i>\n <\/div>\n \n

\n Pas de sympt\u00f4mes gastro-intestinaux non contr\u00f4l\u00e9s<\/strong>\n <\/h3>\n
\n <\/div>\n <\/div>\n \n <\/div>\n<\/div>\n<\/div>\n\n\n
\n
\n
\n\n

Pour obtenir une liste compl\u00e8te des crit\u00e8res d\u2019inclusion et d\u2019exclusion<\/span><\/p>\n<\/div>\n \n \n <\/div>\n<\/div>\n\n<\/div>\n\n\n

\n
\n \n T\u00e9l\u00e9charger le guide de s\u00e9lection des patients <\/i>\n <\/a>\n <\/div>\n\n<\/div>\n\n\n\n
\n
\n
\n\n
\n\n \n

Points principaux de l\u2019essai AIRFLOW-3 <\/h2>\n \n \n <\/div>\n\n \n <\/div>\n <\/div>\n\n<\/div>\n\n\n\n\n
\n
\n
\n\n

Informations sur l\u2019\u00e9tude<\/strong><\/h2>\n

Essai pivot<\/span>
\n<\/span>randomis\u00e9 (1:1) <\/span> \u2022 en double aveugle<\/span> \u2022 contr\u00f4l\u00e9 par traitement simul\u00e9<\/span> \u2022 approuv\u00e9 par la FDA<\/span><\/p>\n<\/div>\n \n \n <\/div>\n<\/div>\n\n<\/div>\n\n\n

\n
\n
\n\n
\n

Essai multicentrique <\/h3>\n

\u00c9tats-Unis et Europe<\/p>\n <\/div>\n

\n

Nombre de patients <\/h3>\n

Jusqu\u2019\u00e0 400 patients <\/p>\n <\/div>\n \n <\/div>\n <\/div>\n<\/div>\n\n<\/div>\n\n

\n
\n<\/div>\n\n\n\n\n
\n
\n
\n\n

Crit\u00e8re d\u2019\u00e9valuation principal :<\/strong><\/p>\n

Comparaison, entre le groupe de traitement et le groupe de traitement simul\u00e9, de la probabilit\u00e9 pour les patients \u00e0 pr\u00e9senter une exacerbation mod\u00e9r\u00e9e ou s\u00e9v\u00e8re un an apr\u00e8s l\u2019intervention<\/span><\/p>\n<\/div>\n \n \n <\/div>\n<\/div>\n\n<\/div>\n\n\n

\n
\n \n Pour en savoir plus <\/i>\n <\/a>\n <\/div>\n\n<\/div>\n\n\n
\n
\n\n
\n
\n
\n
\n

Votre patient serait-il un bon candidat ?<\/h2>\n <\/div>\n <\/div>\n\n
\n

Pour les patients inclus l\u2019essai clinique AIRFLOW-3 pr\u00e9voit\u00a0:<\/p>\n